Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

WILMINGTON, Del., June 01, 2025--(BUSINESS WIRE)--Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI ® (durvalumab) in combination ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Imfinzi combined with FLOT chemotherapy improved EFS in resectable gastric/GEJ adenocarcinoma, with no new safety signals observed. Adverse effects were comparable between Imfinzi and placebo arms, ...

Recommendation based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant ...

Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI ® (durvalumab) in combination with standard-of-care FLOT (fluorouracil ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that its Imfinzi (durvalumab) has been recommended for approval in the European Union to treat muscle-invasive ...